During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.
Patrick Hagen, MD
Patrick Hagen, MD, is an associate professor at Loyola Medicine.
Articles by Patrick Hagen, MD
